Grams Medical Inc.
Letter data
- Company
- Grams Medical Inc.
- Recipient
- Grams Medical Inc. | United States
- Issue date
- 2018-03-28
- Posted date
- Not available
- FDA office
- United States
- Subject
- Not available
- Product
- Not available
- CMS ID
- 482761
- Reference number
- Not available
- FEI
- Not available
- Inspection dates
- Not available
Normalized citations
21 CFR: None found
21 U.S.C.: None found
Related FDA links
No related FDA letter link is present in the source index.
Full source text
CLOSEOUT LETTER
Grams Medical Inc.
MARCS-CMS 482761 —
March 28, 2018
More Warning Letters
Warning Letters
About Warning and Close-Out Letters
Recipient:
Grams Medical Inc.
United States
Issuing Office:
United States
Office of Medical Device and Radiological Health Operations
Division 3West
19701 Fairchild
Irvine, CA 92612
VIA UNITED PARCEL SERVICE
March 28, 2018
CMS Case ID: 482761
UPS Overnight
Guenter Grams, President and CEO
Grams Medical Inc.
2443 Norse Ave
Costa Mesa, California 92627
Dear Mr. Grams:
The Food and Drug Administration has completed an evaluation of your corrective actions in response to our Warning Letter 24-16, dated March 17, 2016. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Kelly D. Sheppard
Director, Compliance Branch
Content current as of:
05/11/2018